We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, April 6th:
Avid Technology, Inc. : This company that develops, markets, sells, and supports software, hardware, and integrated solutions for video and audio content creation, management, and distribution carries a Zacks Rank #1 (Strong Buy), has witnessed the Zacks Consensus Estimate for its current year earnings increasing 6.2% over the last 60 days.
Ultra Clean Holdings, Inc. (UCTT - Free Report) : This company that designs, develops, prototypes, engineers, manufactures, and tests production tools, modules, and subsystems for the semiconductor and display capital equipment industries carries a Zacks Rank #1, has witnessed the Zacks Consensus Estimate for its current year earnings increasing 35% over the last 60 days.
Collegium Pharmaceutical, Inc. (COLL - Free Report) : This specialty pharmaceutical company that develops and commercializes various products for patients suffering from pain carries a Zacks Rank #2 (Buy), has witnessed the Zacks Consensus Estimate for its current year earnings increasing more than 100% over the last 60 days.
Collegium Pharmaceutical, Inc. Price and Consensus
CRA International, Inc. (CRAI - Free Report) : This consulting company that provides economic, financial, and management consulting services carries a Zacks Rank #2, has witnessed the Zacks Consensus Estimate for its current year earnings increasing 0.9% over the last 60 days.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
Image: Bigstock
Top Ranked Growth Stocks to Buy for April 6th
Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, April 6th:
Avid Technology, Inc. : This company that develops, markets, sells, and supports software, hardware, and integrated solutions for video and audio content creation, management, and distribution carries a Zacks Rank #1 (Strong Buy), has witnessed the Zacks Consensus Estimate for its current year earnings increasing 6.2% over the last 60 days.
Avid Technology, Inc. Price and Consensus
Avid Technology, Inc. price-consensus-chart | Avid Technology, Inc. Quote
Avid Technology has a PEG ratio of 0.35, compared with 1.74 for the industry. The company possesses a Growth Score of A.
Avid Technology, Inc. PEG Ratio (TTM)
Avid Technology, Inc. peg-ratio-ttm | Avid Technology, Inc. Quote
Ultra Clean Holdings, Inc. (UCTT - Free Report) : This company that designs, develops, prototypes, engineers, manufactures, and tests production tools, modules, and subsystems for the semiconductor and display capital equipment industries carries a Zacks Rank #1, has witnessed the Zacks Consensus Estimate for its current year earnings increasing 35% over the last 60 days.
Ultra Clean Holdings, Inc. Price and Consensus
Ultra Clean Holdings, Inc. price-consensus-chart | Ultra Clean Holdings, Inc. Quote
Ultra Clean Holdings has a PEG ratio of 0.48, compared with 2.08 for the industry. The company possesses a Growth Score of A.
Ultra Clean Holdings, Inc. PEG Ratio (TTM)
Ultra Clean Holdings, Inc. peg-ratio-ttm | Ultra Clean Holdings, Inc. Quote
Collegium Pharmaceutical, Inc. (COLL - Free Report) : This specialty pharmaceutical company that develops and commercializes various products for patients suffering from pain carries a Zacks Rank #2 (Buy), has witnessed the Zacks Consensus Estimate for its current year earnings increasing more than 100% over the last 60 days.
Collegium Pharmaceutical, Inc. Price and Consensus
Collegium Pharmaceutical, Inc. price-consensus-chart | Collegium Pharmaceutical, Inc. Quote
Collegium Pharmaceutical has a PEG ratio of 0.33, compared with 0.51 for the industry. The company possesses a Growth Score of B.
Collegium Pharmaceutical, Inc. PEG Ratio (TTM)
Collegium Pharmaceutical, Inc. peg-ratio-ttm | Collegium Pharmaceutical, Inc. Quote
CRA International, Inc. (CRAI - Free Report) : This consulting company that provides economic, financial, and management consulting services carries a Zacks Rank #2, has witnessed the Zacks Consensus Estimate for its current year earnings increasing 0.9% over the last 60 days.
Charles River Associates Price and Consensus
Charles River Associates price-consensus-chart | Charles River Associates Quote
CRA International has a PEG ratio of 0.74, compared with 1.33 for the industry. The company possesses a Growth Score of B.
Charles River Associates PEG Ratio (TTM)
Charles River Associates peg-ratio-ttm | Charles River Associates Quote
See the full list of top ranked stocks here.
Learn more about the Growth score and how it is calculated here.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>